P
pistoia
New member
Member
- Joined
- Feb 10, 2015
- Messages
- 2
- Points
- 1
Many body builders who take testosterone (and also men who are on testosterone replacement therapy (TRT) for medical reasons) need to be aware of the fact that testosterone converts to the female hormone estradiol through the aromatase enzyme. High levels of testosterone can cause high levels of estradiol, which in turn can cause the highly undesired development of female body characteristics, including gynecomastia.
To prevent these effects from taking place, there are two options:
The best solution is to take an aromatase inhibitor. For years, the most popular choice has been Anastrozole (the generic name for Arimidex). Recently, body builders and men on TRT have found another, more powerful aromatase inhibitor: Letrozole (the generic name for Femara). According to a recent scientific study, Letrozole is indeed much more powerful than Anastrozole:
To prevent these effects from taking place, there are two options:
- Estrogen blockers[/*:m:3t5jcmy2]
- Aromatase inhibitors[/*:m:3t5jcmy2]
The best solution is to take an aromatase inhibitor. For years, the most popular choice has been Anastrozole (the generic name for Arimidex). Recently, body builders and men on TRT have found another, more powerful aromatase inhibitor: Letrozole (the generic name for Femara). According to a recent scientific study, Letrozole is indeed much more powerful than Anastrozole:
[...] Letrozole suppresses tissue estrone (E1), estradiol (E2) and estrone sulfate (E1S) levels significantly below what has previously been recorded with anastrozole (89.0%, 83.4%, and 72.9% suppression, respectively). [...] Letrozole consistently suppressed each plasma estrogen fraction below the levels recorded for anastrozole: E2 (average suppression by 95.2% versus 92.8%; P = 0.018), E1 (98.8% suppression versus 96.3%; P = 0.003), and E1S (98.9% suppression versus 95.3%; P = 0.003).
Conclusion: Our data reveals that letrozole (2.5 mg o.d.) is more effective compared with anastrozole (1.0 mg o.d.) with respect to tissue as well as plasma estrogen suppression